Skip to main content
TipRanks
Go Ultimate75% OFF

Eastwood Bio-Medical Canada (EBM) AI Stock Analysis

5 Followers
TSE:EBM

Eastwood Bio-Medical Canada

(TSXV:EBM)

Select Model
Rating:46Neutral
Price Target:CAD 1.50â–¼(-7.98% Downside)
Action:reiterated
Date:10/01/26

The overall score is severely depressed by the company's near-insolvent financial state, with negative equity, persistent losses, and cash burn posing an existential risk. While the stock exhibits strong bullish technical momentum, this is a high-risk speculative trend unsupported by fundamentals. The deeply negative P/E ratio confirms the lack of earnings-based value.

Positive Factors
Revenue reboundThe sharp TTM revenue rebound indicates that demand for the company’s products or services has recovered materially after prior volatility. If maintained, stronger sales can improve operating leverage, support reinvestment, and provide a broader base from which the business can pursue sustained growth.
Negative Factors
Deeply negative equityDeeply negative and worsening equity reflects accumulated losses and leaves the company with a weak capital base. This reduces financial flexibility, raises financing and refinancing risk, and may constrain EBM’s ability to fund expansion or withstand setbacks without additional capital.

Eastwood Bio-Medical Canada (EBM) vs. iShares MSCI Canada ETF (EWC)

-50%-25%0%25%50%75%100%125%TSE:EBM+81.11%EWC+11.69%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
CAD 112.28M
Dividend Yield
―
Average Volume (3M)
7,031
Price to Earnings (P/E)
-525.8
Beta (1Y)
0.54
Revenue Growth
36.59%
EPS Growth
43.33%
Country
Canada
Employees
3
Sector
Healthcare
Sector Strength
51
Industry
Medical - Pharmaceuticals

Eastwood Bio-Medical Canada Business Overview & Revenue Model

Company Description

Eastwood Bio-Medical Canada Inc., established in Richmond, Canada, in 2010, is a company focused on the worldwide marketing and distribution of natural health products. Operating under the Eleotin brand, their offerings are available across Canada, t...

Eastwood Bio-Medical Canada Financial Statement Overview

Summary

Financial health is critically poor. The company is technically insolvent with negative equity of -$1.78M, deeply negative profit margins (-28.5% net), and negative operating and free cash flow. A recent revenue spike to $812K and a 66.3% gross margin offer a faint glimmer of product viability, but this is overwhelmed by the unsustainable cost structure and cash burn.

Income Statement

18Very Negative

Balance Sheet

5Very Negative

Cash Flow

10Very Negative
Financial statement breakdown
BreakdownTTMJan 2026Jan 2025Oct 2023Oct 2022Jan 2022
Income Statement
Total Revenue812.12K782.08K702.08K867.94K1.30M981.05K
Gross Profit538.18K506.03K454.39K440.51K902.74K458.37K
EBITDA-238.60K-309.73K-342.05K-410.58K-32.33K-495.50K
Net Income-231.56K-332.77K-455.87K-546.60K-160.58K-611.34K
Balance Sheet
Total Assets256.96K218.77K274.29K489.14K584.53K691.12K
Cash, Cash Equivalents and Short-Term Investments3,52817.70K018.45K39.84K20.87K
Total Debt63.65K78.01K79.61K23.08K62.25K31.35K
Total Liabilities2.04M1.85M1.57M1.33M878.73K835.44K
Stockholders Equity-1.78M-1.63M-1.30M-840.80K-294.20K-144.32K
Cash Flow
Free Cash Flow-9,42019.30K-15.22K-16.89K-7,299-121.79K
Operating Cash Flow-9,42819.30K-15.22K-16.89K-4,294-116.21K
Investing Cash Flow0000-3,005-5,574
Financing Cash Flow-7,688-211-4,619-4,50326.27K20.00K

Eastwood Bio-Medical Canada Technical Analysis

Technical Analysis SentimentNeutral
Last Price1.63

Price Trends

50DMA1.83Negative
100DMA1.59Positive
200DMA1.18Positive

Market Momentum

MACD-0.05Positive
RSI38.59Neutral
STOCH34.49Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:EBM, the sentiment is Neutral. The current price of 1.63 is below the 20-day moving average (MA) of 1.81, below the 50-day MA of 1.83, and above the 200-day MA of 1.18, indicating a neutral trend. The MACD of -0.05 indicates Positive momentum. The RSI at 38.59 is Neutral, neither overbought nor oversold. The STOCH value of 34.49 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TSE:EBM.

Eastwood Bio-Medical Canada Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

TSE:EBM against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
TSE:EBMTSE:EBM46NeutralCAD 112.28M-525.8113.66%―36.59%43.33%
TSE:ARCHTSE:ARCH43NeutralCAD 59.78M-20.7074.79%――-15.53%
TSE:ATLETSE:ATLE42NeutralCAD 37.30M-0.76-2099.75%―-96.13%88.13%
TSE:ADKTSE:ADK38UnderperformCAD 28.30M-5.699999.00%―-36.92%13.03%
TSE:SONATSE:SONA37UnderperformCAD 31.93M-12.15448.05%――24.65%

* Healthcare Sector Average

Performance Comparison

-50%0%50%100%TSE:EBMTSE:ARCHTSE:ADKTSE:ATLETSE:ZYUSTSE:SONADec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
TSE:EBM and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
TSE:EBMEastwood Bio-Medical Canada1.630.6363.00%
TSE:ARCHArch Biopartners0.88-0.17-16.19%
TSE:ADKDiagnos Inc0.23-0.08-24.19%
TSE:ATLEWillow Biosciences0.08-0.07-46.67%
TSE:ZYUSZyus Life Sciences Corporation0.39-0.21-35.83%
TSE:SONASona Nanotech, Inc0.26-0.24-48.00%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 01, 2026